1h Free Analyst Time
The publisher's latest Pharmaceutical and Healthcare disease pipeline guide Diabetic Neuropathy - Drugs In Development, 2022, provides an overview of the Diabetic Neuropathy (Metabolic Disorders) pipeline landscape.Speak directly to the analyst to clarify any post sales queries you may have.
Diabetic neuropathy, a common complication of diabetes, is damage to the nerves that allow feeling things such as pain. Symptoms include tingling, numbness, burning and pain. The predisposing factors are obesity, hypertension, high lipid and sugar levels, smoking, etc. It may be managed by medication and dietary modification.
Report Highlights
The publisher's Pharmaceutical and Healthcare latest pipeline guide Diabetic Neuropathy - Drugs In Development, 2022, provides comprehensive information on the therapeutics under development for Diabetic Neuropathy (Metabolic Disorders), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.The Diabetic Neuropathy (Metabolic Disorders) pipeline guide also reviews of key players involved in therapeutic development for Diabetic Neuropathy and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies/Universities/Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, Preclinical and Discovery stages are 1, 8, 7, 18 and 6 respectively. Similarly, the Universities portfolio in Preclinical stages comprises 1 molecules, respectively.
Diabetic Neuropathy (Metabolic Disorders) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from the publisher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
Scope
- The pipeline guide provides a snapshot of the global therapeutic landscape of Diabetic Neuropathy (Metabolic Disorders).
- The pipeline guide reviews pipeline therapeutics for Diabetic Neuropathy (Metabolic Disorders) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Diabetic Neuropathy (Metabolic Disorders) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Diabetic Neuropathy (Metabolic Disorders) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Diabetic Neuropathy (Metabolic Disorders)
Reasons to Buy
- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Diabetic Neuropathy (Metabolic Disorders).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Diabetic Neuropathy (Metabolic Disorders) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Table of Contents
- Introduction
- Report Coverage
- Diabetic Neuropathy - Overview
- Diabetic Neuropathy - Therapeutics Development
- Pipeline Overview
- Pipeline by Companies
- Pipeline by Universities/Institutes
- Products under Development by Companies
- Products under Development by Universities/Institutes
- Diabetic Neuropathy - Therapeutics Assessment
- Assessment by Target
- Assessment by Mechanism of Action
- Assessment by Route of Administration
- Assessment by Molecule Type
- Diabetic Neuropathy - Companies Involved in Therapeutics Development
- Achelios Therapeutics Inc
- Applied Therapeutics Inc
- Beijing Tide Pharmaceutical Co Ltd
- Bexion Pharmaceuticals LLC
- Celon Pharma SA
- CSPC Pharmaceutical Group Ltd
- Epigen Biosciences Inc
- Exodos Life Sciences Limited Partnership
- Frontbio Co Ltd
- G&P Bioscience Co Ltd
- Glycadia Inc
- Grunenthal GmbH
- Han Wha Pharma Co Ltd
- Ion Channel Pharmacology LLC
- JanOne Inc
- Korea United Pharm Inc
- Medifron DBT Co Ltd
- Mitsubishi Tanabe Pharma Corp
- Omeros Corp
- Ono Pharmaceutical Co Ltd
- Palisade Bio, Inc
- Praetego Inc
- Pure Green Pharmaceuticals Inc
- Reata Pharmaceuticals Inc
- Releviate Therapeutics
- Shandong Huizhi Pharmaceutical Technology Co Ltd
- Sichuan Haisco Pharmaceutical Co Ltd
- Sonnet BioTherapeutics Holdings Inc
- WEX Pharmaceuticals Inc
- Winsantor Inc
- Zelira Therapeutics Ltd
- Zhejiang Pharmaceutical Co Ltd
- Diabetic Neuropathy - Drug Profiles
- A-717 - Drug Profile
- Product Description
- Mechanism Of Action
- atexakin alfa - Drug Profile
- Product Description
- Mechanism Of Action
- BXQ-350 - Drug Profile
- Product Description
- Mechanism Of Action
- caficrestat - Drug Profile
- Product Description
- Mechanism Of Action
- CPL-207280CA - Drug Profile
- Product Description
- Mechanism Of Action
- elismetrep - Drug Profile
- Product Description
- Mechanism Of Action
- EPGN-2154 - Drug Profile
- Product Description
- Mechanism Of Action
- FB-118B1 - Drug Profile
- Product Description
- Mechanism Of Action
- GB-102 - Drug Profile
- Product Description
- Mechanism Of Action
- GLY-230 - Drug Profile
- Product Description
- Mechanism Of Action
- HSK-16149 - Drug Profile
- Product Description
- Mechanism Of Action
- ketoprofen - Drug Profile
- Product Description
- Mechanism Of Action
- KU-32 - Drug Profile
- Product Description
- Mechanism Of Action
- lidocaine - Drug Profile
- Product Description
- Mechanism Of Action
- MDR-16523 - Drug Profile
- Product Description
- Mechanism Of Action
- MDR-652 - Drug Profile
- Product Description
- Mechanism Of Action
- Monoclonal Antibodies to Inhibit MASP-2 for Diabetic Complications and Rheumatoid Arthritis - Drug Profile
- Product Description
- Mechanism Of Action
- NSI-189 - Drug Profile
- Product Description
- Mechanism Of Action
- ONO-2910 - Drug Profile
- Product Description
- Mechanism Of Action
- Peptide to Activate G Protein-Coupled Receptor Mas for Cardiovascular, Metabolic Disorders and Male Health - Drug Profile
- Product Description
- Mechanism Of Action
- PGDN-20WS - Drug Profile
- Product Description
- Mechanism Of Action
- pirenzepine - Drug Profile
- Product Description
- Mechanism Of Action
- PTG-6 - Drug Profile
- Product Description
- Mechanism Of Action
- PTG-640 - Drug Profile
- Product Description
- Mechanism Of Action
- PTG-641 - Drug Profile
- Product Description
- Mechanism Of Action
- resiniferatoxin - Drug Profile
- Product Description
- Mechanism Of Action
- RLVT-1402 - Drug Profile
- Product Description
- Mechanism Of Action
- RLVT-903 - Drug Profile
- Product Description
- Mechanism Of Action
- RTA-901 - Drug Profile
- Product Description
- Mechanism Of Action
- Small Molecule for Algodystrophy, Chemotherapy Induced Peripheral Neuropathy, Diabetic Peripheral Neuropathy and Pain - Drug Profile
- Product Description
- Mechanism Of Action
- Small Molecule for Diabetic Peripheral Neuropathy - Drug Profile
- Product Description
- Mechanism Of Action
- Small Molecule to Agonize MOR1 for Chemotherapy Induced Peripheral Neuropathy, Diabetic Peripheral Neuropathy and Postherpetic Neuralgia - Drug Profile
- Product Description
- Mechanism Of Action
- Small Molecules to Agonize CB1 and CB2 for Diabetic Neuropathy and Peripheral Arterial Disease - Drug Profile
- Product Description
- Mechanism Of Action
- Small Molecules to Target Plasminogen for Chronic Inflammatory Diseases and Diabetic Neuropathy - Drug Profile
- Product Description
- Mechanism Of Action
- sodium nitrite SR - Drug Profile
- Product Description
- Mechanism Of Action
- SYHA-1402 - Drug Profile
- Product Description
- Mechanism Of Action
- Tetrodotoxin - Drug Profile
- Product Description
- Mechanism Of Action
- UI-016 - Drug Profile
- Product Description
- Mechanism Of Action
- UI-048 - Drug Profile
- Product Description
- Mechanism Of Action
- YJ-001 - Drug Profile
- Product Description
- Mechanism Of Action
- YJC-007 - Drug Profile
- Product Description
- Mechanism Of Action
- Diabetic Neuropathy - Dormant Projects
- Diabetic Neuropathy - Discontinued Products
- Diabetic Neuropathy - Product Development Milestones
- Featured News & Press Releases
- Aug 02, 2021: Innovative drug HSK16149 capsule was approved to carry out phase II clinical trial of "auxiliary opioid analgesia"
- Jun 02, 2021: Innovative drug HSK16149 capsule new indications obtained IND application "Notice of Acceptance"
- May 13, 2021: Pure Green Pharmaceuticals reports unexpected results of a randomized, placebo controlled clinical trial with sublingual CBD in patients with painful diabetic peripheral neuropathy
- Apr 01, 2021: Celon Pharma announces CPL’280, second generation oral GPR40 agonist, meets primary endpoint in phase 1 trial
- Jan 25, 2021: Sonnet BioTherapeutics announces the successful completion of a non-human primate toxicology study of SON-080
- Sep 30, 2020: Praetego receives NIH phase 2 STTR funding to advance novel amadorin drug candidates for diabetic peripheral neuropathy
- Apr 12, 2019: “SYHA1402” for the treatment of diabetic neuropathy was granted clinical trial approval
- Jun 01, 2018: Reata Selected to Present on its Early-Stage Program RTA 901 at the BIO International Convention
- Mar 16, 2018: Reata to Present on its Diabetic Neuropathy Drug Candidate RTA-901 at the BIO Asia International Conference
- Aug 02, 2017: Neuralstem Awarded $~1MM Grant by NIH to Continue Preclinical Research into the Potential of NSI-189 for Treatment of Diabetic Neuropathy
- Sep 04, 2016: Salvianolic acid A tablets developed by the National Drug Screening Center received clinical approval
- Appendix
- Methodology
- Coverage
- Secondary Research
- Primary Research
- Expert Panel Validation
- Contact the Publisher
- Disclaimer
- Number of Products under Development for Diabetic Neuropathy, 2022
- Number of Products under Development by Companies, 2022
- Number of Products under Development by Universities/Institutes, 2022
- Products under Development by Companies, 2022
- Products under Development by Universities/Institutes, 2022
- Number of Products by Stage and Target, 2022
- Number of Products by Stage and Mechanism of Action, 2022
- Number of Products by Stage and Route of Administration, 2022
- Number of Products by Stage and Molecule Type, 2022
- Diabetic Neuropathy - Dormant Projects, 2022
- Diabetic Neuropathy - Discontinued Products, 2022
- Number of Products under Development for Diabetic Neuropathy, 2022
- Number of Products under Development by Companies, 2022
- Number of Products by Top 10 Targets, 2022
- Number of Products by Stage and Top 10 Targets, 2022
- Number of Products by Top 10 Mechanism of Actions, 2022
- Number of Products by Stage and Top 10 Mechanism of Actions, 2022
- Number of Products by Routes of Administration, 2022
- Number of Products by Stage and Routes of Administration, 2022
- Number of Products by Molecule Types, 2022
- Number of Products by Stage and Molecule Types, 2022
Companies Mentioned (Partial List)
A selection of companies mentioned in this report includes, but is not limited to:
- Achelios Therapeutics Inc
- Applied Therapeutics Inc
- Beijing Tide Pharmaceutical Co Ltd
- Bexion Pharmaceuticals LLC
- Celon Pharma SA
- CSPC Pharmaceutical Group Ltd
- Epigen Biosciences Inc
- Exodos Life Sciences Limited Partnership
- Frontbio Co Ltd
- G&P Bioscience Co Ltd
- Glycadia Inc
- Grunenthal GmbH
- Han Wha Pharma Co Ltd
- Ion Channel Pharmacology LLC
- JanOne Inc
- Korea United Pharm Inc
- Medifron DBT Co Ltd
- Mitsubishi Tanabe Pharma Corp
- Omeros Corp
- Ono Pharmaceutical Co Ltd
- Palisade Bio, Inc
- Praetego Inc
- Pure Green Pharmaceuticals Inc
- Reata Pharmaceuticals Inc
- Releviate Therapeutics
- Shandong Huizhi Pharmaceutical Technology Co Ltd
- Sichuan Haisco Pharmaceutical Co Ltd
- Sonnet BioTherapeutics Holdings Inc
- WEX Pharmaceuticals Inc
- Winsantor Inc
- Zelira Therapeutics Ltd
- Zhejiang Pharmaceutical Co Ltd
